Clinical trial · Interventional
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium
NCT00191971CI-TRIAL-00000957completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Transitional Cell | Transitional Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Urologic Neoplasms | Urinary Tract Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine | Drug | Gemcitabine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response rate
Secondary outcomes (2)
- measure
- Progression-free survival
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically and/or cytologically confirmed TCC * Received 1st line chemotherapy for locally advanced or metastatic TCC with CDDP regimen * To have at least one measurable region * PS: 0-2 * To have adequate organ function (bone marrow, liver and renal function) Exclusion Criteria: * To have Interstitial pneumonia or pulmonary fibrosis * Within 4 weeks after the latest chemotherapy or radiotherapy * To have brain metastasis with symptom * To have severe complication (cardiac infarction, infection, drug hyper sensitivity or diabetes)
References
Publications (0)
Data not yet available
No reference posted for this study.